Cardiology
Cardiac Surgery
Sirolimus- versus Paclitaxel-Eluting Stent Implantation for Unprotected Left Main Coronary Artery StenosisLee S.H.a · Ko Y.-G.b · Jang Y.b · Kwon H.M.c · Lee S.-H.g · Yoon J.H.g · Park S.H.d · Kim B.O.e · Jeon D.W.h · Yang J.Y.h · Ryu S.-K.faKangnam Sacred Heart Hospital, bYonsei Cardiovascular Center, cYongdong Severance Hospital, dEhwa Women’s University Mokdong Hospital, eSanggye Paik Hospital and fNowon Eulji Hospital, Seoul, gWonju Christian Hospital, Wonju, and hNHIC Ilsan Hospital, Goyang, Republic of Korea
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 15, 2005
Accepted: May 17, 2005
Published online: October 04, 2005
Issue release date: September 2005
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Abstract
We performed this study in order to compare the immediate and mid-term outcomes of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in lesions of the unprotected left main coronary artery (LMCA). We assessed 54 patients from 5 centers who had undergone unprotected LMCA stenting (35 SES and 19 PES). The procedural success rates were 100 and 95%, respectively, in the SES and PES patients (p = 0.19). At the 6-month clinical follow-up, the event-free probability was 100% in the SES group, and 88% in the PES group (p = 0.07). At the 6-month angiographic follow-up (n = 24), the SES group exhibited a slightly lower late loss than did the PES group (0.24 ± 0.44 vs. 0.65 ± 0.60 mm, p = 0.09), and the restenosis rates were 8 and 9% (p = 0.94) in the SES and PES patients, respectively. In conclusion, both groups exhibited excellent in-hospital and 6-month outcomes with no significant differences between them.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Park SJ, Park SW, Hong MK, Cheong SS, Lee CW, Kim JJ, Mintz GS, Leon MB: Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. J Am Coll Cardiol 1998;31:37–42.
- Silvestri M, Baragan P, Sainsous J, Bayet G, Simeoni JB, Roquebert PO, Macaluso G, Bouvier JL, Comet B: Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 2000;35:1543–1550.
- Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, Lee CH, Ruiter A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feijter P, van Domburg R, Serruys PW: Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 2003;92:327–329.
- Arampatzis CA, Lemos PA, Hoye A, Saia F, Tanabe K, van der Giessen WJ, Smits PC, McFadden E, de Feyter P, Serruys PW: Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc Interv 2004;62:292–296.
- De Lezo JS, Medina A, Pan M, Delgado A, Segura J, Pavlovic K, Melian F, Romero M, Burgos L, Hernandez E, Urena I, Herrador J: Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J 2004;148:481–485.
- Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, Kim JJ, Mintz GS, Park SW: Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol 2005;45:351–356.
- The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932–936.
- Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T: Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004;25:902–919.
- Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ: A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004;364:583–591.
- Valgimigli M, van Mieghem CA, Ong AT, Aok J, Granillo GA, McFadden EP, Kappetein AP, de Feyter PJ, Smits PC, Regar E, Van der Giessen WJ, Sianos G, de Jaegere P, Van Domburg RT, Serruys PW: Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insight from the Rapamycin-Eluting and Taxus Stent Evaluated at Rotterdam Cardiology registries (RESEARCH and T-SEARCH). Circulation 2005;111:1383–1389.
- Ikovou I, Stankovic G, Montorfano M, Airoldi F, Chieffo A, Sangiorgi GM, Carlino M, Corvaja N, Iassen M, Rogacka R, Vitrella G, Colombo A: Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate? Catheter Cardiovasc Interv 2005;64:129–133.
- Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS: A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537–1545.
- Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C: A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. J Am Coll Cardiol 2005;45:308–311.
- Kastrati A, Mehilli J, von Beckerath N, Dib ra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A, for ISAR-DESIRE Study Investigators: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165–171.
Article / Publication Details
Received: April 15, 2005
Accepted: May 17, 2005
Published online: October 04, 2005
Issue release date: September 2005
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
